ELSEVIER

Contents lists available at ScienceDirect

Virus Research



journal homepage: www.elsevier.com/locate/virusres

Signal hotspot mutations in SARS-CoV-2 genomes evolve as the virus spreads and actively replicates in different parts of the world

Stefanie Weber^a, Christina Ramirez^b, Walter Doerfler^{a, c, *}

^a Institute for Clinical and Molecular Virology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, 91054, Erlangen, Germany

^b Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA, 90095-1772, USA

^c Institute of Genetics, University of Cologne, 50674, Cologne, Germany

ARTICLE INFO

Keywords: Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) Sequence comparisons between 570 viral genomes to Wuhan isolate Selection of viral hotspot mutations Impact on replication-relevant viral proteins Consequences for secondary and tertiary structures of viral RNA Questions about immunogenesis and vaccine development

ABSTRACT

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China late in 2019. Nine months later (Sept. 23, 2020), the virus has infected > 31.6 million people around the world and caused > 971.000 (3.07 %) fatalities in 220 countries and territories. Research on the genetics of the SARS-CoV-2 genome, its mutants and their penetrance can aid future defense strategies. By analyzing sequence data deposited between December 2019 and end of May 2020, we have compared nucleotide sequences of 570 SARS-CoV-2 genomes from China, Europe, the US, and India to the sequence of the Wuhan isolate. During worldwide spreading among human populations, at least 10 distinct hotspot mutations had been selected and found in up to > 80 % of viral genomes. Many of these mutations led to amino acid exchanges in replication-relevant viral proteins. Mutations in the SARS-CoV-2 genome would also impinge upon the secondary structure of the viral RNA molecule and its repertoire of interactions with essential cellular and viral proteins. The increasing frequency of SARS-CoV-2 mutation hotspots might select for dangerous viral pathogens. Alternatively, in a 29.900 nucleotide-genome, there might be a limit to the number of mutable and selectable sites which, when exhausted, could prove disadvantageous to viral survival. The speed, at which novel SARS-CoV-2 mutants are selected and dispersed around the world, could pose problems for the development of vaccines and therapeutics.

1. Introduction

The Coronavirus Disease 19 (COVID-19) pandemic has presented unusual challenges to genetic and virological analyses (Fauci et al., 2020; Na et al., 2020; Qun et al., 2020). One of the major scientific problems confronted with by the SARS-CoV-2 pandemic lies in our limited understanding of the interactions between the viral and the human host genomes and the latter's defense mechanisms against this pathogen. The frequency of new mutations in viral genomes depends on a multitude of viral and host factors which determine mutant selection. Nucleic acid sequence and the presence of repair mechanisms in the viral genome, the secondary and tertiary structures of the viral genome; the intensity of viral replication, the host's genetically determined defense mechanisms, environmental factors, like ambient temperature, UV radiation, among many unidentified factors, all contribute to the stability or instability of viral genomes.

SARS-CoV-2, like Sars-CoV-1 (2003/2004), and MERS-CoV (2012),

which were also responsible for human severe acute lung diseases, belongs to the group of beta-coronaviruses. Human beta-coronaviruses OC43 or HKU1 cause less severe seasonal upper respiratory tract infections. Coronaviruses carry plus-strand RNA genomes of between 26,000 and 32,000 nucleotides in length, the largest genomes among RNA viruses (Helmy et al., 2020; Coronavirus disease pandemic, 2020). During viral replication, a virus-encoded exonuclease and additional non-structural proteins form a replication complex with the viral RNA-dependent-RNA polymerase (RdRp) to generate new virion-packaged genomes (Hartenian et al., 2020; Subissi et al., 2014; Wang et al., 2020). This complex functions in proof-reading and corrects copying errors by the viral RdRp (Subissi et al., 2014). For SARS-CoV-2, this proof reading mechanism is still under study. The debate that during SARS-CoV-2 RNA replication the generation of mutants remains low in comparison to other plus-strand RNA viruses, has not been resolved. However, for our understanding of this epidemic, it will be more relevant to research how efficiently SARS-CoV-2 RNA mutants are selected

* Corresponding author at: Institute for Clinical and Molecular Virology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Schlossgarten 4, D-91054, Erlangen, Germany.

E-mail address: walter.doerfler@t-online.de (W. Doerfler).

https://doi.org/10.1016/j.virusres.2020.198170

Received 1 August 2020; Received in revised form 18 September 2020; Accepted 19 September 2020 Available online 24 September 2020 0168-1702/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). and become dominant in the course of the COVID-19 pandemic. Mutations affecting the secondary and tertiary structures of SARS-CoV-2 RNA might be the most relevant ones when considering selection for viral survival among human populations.

There are unique aspects of SARS-CoV-2 genetics and mutagenesis in that the virus managed to jump very recently from mammalian to human hosts and thereafter expanded with unprecedented speed among a world population of almost 8 billion who live under vastly different geographic and socioeconomic conditions. The growing distance from that critical animal-to-human transition point and the chance for rapid propagation under an ensemble of environmental factors and human genetic backgrounds has enabled SARS-CoV-2 genomes to select for replication-efficient mutations. The plasticity of the SARS-CoV-2 genome has motivated us to study the frequency of occurrence, the types of nucleotide exchanges and the selection of hotspot mutations in 570 SARS-CoV-2 genomes from isolates that were collected on different continents between December 2019 and the end of May 2020. [NCBI: https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/]. Most observed mutations were point mutations and were found once or a few times among a large number of isolates and may not be significant. There arose, however, strongly selected mutations which show predominant representation and increase in frequency as SARS-CoV-2 explosively replicates in human populations with different geographic, socioeconomic, climatic, and genetic backgrounds.

2. Materials and methods

2.1. Source of sequences and statistical methods employed in the viral mutation analysis

The 570 SARS-CoV-2 genome sequences, which were analyzed for sequence variations, were randomly selected from the NCBI Databank "SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) Sequences"(https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/). The nucleotide sequences included in the comparisons shown in Tables S1 to S6 had been deposited in the data bank as follows:

- Table S1 China: December 23, 2019 to March 18, 2020
- Table S2 Europe: January 01 to May 30, 2020
- Table S3 Germany: February to March 23, 2020
- Table S4 USA I: February 29 to April 26, 2020
- Table S5 USA II: June 12 to July 07, 2020
- Table S6 India: January 27 to May 27, 2020

Nucleotide sequences from China, Europe, the US and India were compared to the reference genome of the SARS-CoV-2 isolate from Wuhan-Hu-1, NCBI Reference Sequence: NC_045512.2. The program Vector NTI Advance[™] 11 (Invitrogen[™]), Tool Align X was used for the alignment of sequences from the US and Germany. Nucleotide sequences of isolates from China, India, and Europe were analyzed with the program Snapgene (GSL Biotech) by using the algorithm MUSCLE (MUltiple Sequence Comparison by Log-Expectation). Amino acid sequences were also analyzed with the program Snapgene. DNA sequence analyses of reverse-transcripts of an RNA genome will have to be considered with oversight. Errors could have been introduced at several steps, e.g., by preferred reading mistakes of the reverse transcriptase due to specific sequence or structural properties of SARS-CoV-2 RNA. We have tried to overcome this obvious complication by analyzing a large number of genomes. More specifically, the absence of the distinct hotspot mutations in the majority of sequences from samples isolated in China, convincingly argues against the possibility of technical problems during the generation of SARS-CoV-2 nucleotide sequences.

In some of the statistical investigations on the data presented, notably comparisons of mutation frequencies between sample collections USA-I and USA-II, the permutation test as well as the Kolmogorov-Smirnov test were applied.

All sequence alignments performed in our laboratory have been stored and are available to inspection on request. The alignments are also accessible via "google drive"

[https://drive.google.com/drive/folders/1fUoqJV_cD_gCeAiWH3iI Q6gWwSJfOqOI?usp=sharing].

3. Results

We have investigated whether and to what extent mutants of the SARS-CoV-2 RNA sequence of 29,903 nucleotides are selected as the virus spreads around the world. At the time of beginning our analyses, about 2,500 nucleotide sequences of SARS-CoV-2 had been published of which 570 were randomly selected and compared to the reference sequence of the Wuhan isolate from late 2019 (NCBI Reference Sequence: NC_045512.2). Fig. 1 was reproduced here as an example of part of the SARS-CoV-2 nucleotide sequence at around position 28,800 and displays 38 viral isolates from different geographic regions (lines 2-38). This sequence was aligned for comparison with the sequence of the Wuhan SARS-CoV-2 isolate (line 1). In 12 of 37 selected sequences, the GGG sequence of the Wuhan sequence (in blue) was mutated to AAC (in white). Additionally, in sequence positions 28,854 and 28,863 a few $C \rightarrow T$ point mutations were apparent. As in this example, all mutations described in this report were identified by inspection and comparison of individual sequences to the Wuhan reference. The results of all sequence comparisons were presented as Supplemental Materials in Tables S1 to S6 and summarized in Table 1. We hypothesize that signal hotspot mutations, in particular those noted in different populations, have functional significance and have been selected for advantages during active viral replication. The possible impact of these mutations on pathogenicity will require further study.

3.1. China

According to the best information available, the world-wide spread of SARS-CoV-2 originated from Wuhan, China, officially in late 2019 (Fauci et al., 2020; Helmy et al., 2020; Na et al., 2020; Qun et al., 2020). In Table S1 (Supplemental Materials), the comparison of nucleotide sequences from 99 Sars-CoV-2 isolates from China with the Wuhan standard sequence revealed a total of 228 deviations from the Wuhan reference. Most notably, in sequence positions 8,782 and 28,144, the point mutations CC to TC and TA to CA, respectively, were observed in 29 isolates out of the 99 sequences examined. Single cytidine (C) to thymidine (T) transitions, which were often seen only 1/99, occasionally 2-5 times in the 99 sequences, were noted in many different sequence locations. The frequent cytidine-to-uridine $(C \rightarrow T)$ transitions, as demonstrated here, might be caused by one of the cellular APOBEC (apolipoprotein B mRNA editing enzyme) cytidine deaminases attempting to restrict viral propagation (Di Giorgio et al., 2020). The high frequency of C to T transitions and its evolutionary implications had been pointed out earlier by Simmonds (2020). Among these C to T transitions, 4 originated from CG dinucleotides in sequence positions 204, 9,967, 25,156, and 29,095. Such mutations can possibly be attributed to the oxidative deamination of a presumptive 5-methyl-C nucleoside (5-mC) to Uridine (U). It is unknown whether 5-mC occurs in SARS-CoV-2 RNA. Single nucleotide mutations, other than C to T transitions, which also occurred only in 1/99 isolates or were present 2-7 times were also documented among the 99 isolates. The functional meaning of these very rare sequence alterations can be considered questionable, unless the frequency of sequence alterations in a certain spot expands with time and/or at certain geographic locations.

Some of the hotspot mutations discovered in isolates from locations other than China, like in positions 3,037, 14,408, 28,854, and 28,881, were only seen each in 2/99 isolates from China (see Table 1). Thus, the frequency of mutations in these locations strongly increased when the virus massively replicated in regions outside China (see below). This was also true for the presumably important GGG \rightarrow AAC mutation in position 28,881 which was found expanded particularly in isolates from Europe (see below and Discussion section).

 SARS-COV 2. NUBL Reference Sequence: No. 045512-22 SARS-COV 2. 2020-01-21 USA:LL M1989713 ZB840 TAGTCGCAACAGTT AGAATGACCAGTA AACCAGTA AACCAGTA AACCAGTA AACCAGTA AACCAGTA AACCAGTA AACCAGTA SAA TTCTCCTGCTAGAATGACCGGCAATGAGGCGGGGGGGGGG	<u>P</u> roject <u>E</u> dit <u>V</u> iew <u>A</u> lign Analyses Assemble Tools <u>W</u> indow <u>H</u> elp								
Image:									
28840 28840 28840 28850 28870 28880 28890 28910 2 SARS-Cov Z, NGBI Reference Sequence NC, 045512.2 28840 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTCTGGAATGGCATGGCATGGCGTG SARS-Cov Z 2020-01-21 USA:1L MT944257 28840 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCTGGCATGGCGTG SARS-Cov Z 2020-03-01 USA:1L MT94483 28840 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCTGGCATGGGT SARS-Cov Z 2020-03-13 USA:1L MT263422 28871 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCTGGCATGGGT SARS-Cov Z 2020-03-13 USA:1L MT263422 28871 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCATGGCAGGTA SARS-Cov Z 2020-03-13 USA:1L MT263423 28801 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCATGGCAGGTA SARS-Cov Z 2020-03-13 USA:1L MT263423 28801 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCAGGGAGGAGGA SARS-Cov Z 2020-03-20 USA:1W MT304865 28810 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGAGGTA, GAA, TI CTCCTGCTGGAATGGCAGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG									
28840 28840 28840 28850 28870 28880 28890 28910 2 SARS-Cov Z, NGBI Reference Sequence NC, 045512.2 28840 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTCTGGAATGGCATGGCATGGCGTG SARS-Cov Z 2020-01-21 USA:1L MT944257 28840 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCTGGCATGGCGTG SARS-Cov Z 2020-03-01 USA:1L MT94483 28840 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCTGGCATGGGT SARS-Cov Z 2020-03-13 USA:1L MT263422 28871 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCTGGCATGGGT SARS-Cov Z 2020-03-13 USA:1L MT263422 28871 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCATGGCAGGTA SARS-Cov Z 2020-03-13 USA:1L MT263423 28801 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCATGGCAGGTA SARS-Cov Z 2020-03-13 USA:1L MT263423 28801 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGTA, GAA, TI CTCCTGCTGGAATGGCAGGGAGGAGGA SARS-Cov Z 2020-03-20 USA:1W MT304865 28810 TAGTGGCAACGETT MAGRAATT AACTCCAGGCAGGGAGGTA, GAA, TI CTCCTGCTGGAATGGCAGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG									
SARS-CoV 2 2020-01-21 USA:IL NI98811 28840 NATICCAGGCALGETY ALGALANT ALCICLAGGCALGETA GAN TITLCCTGCTAGAATGGCGGGGALGGAGGA SARS-CoV 2 2020-01-28 USA:IL MI94821 28840 TATCGCALCAGTY ALGALANT ALCICLAGGCALGETA GAN TITLCCTGCTAGAATGGCGGGGAGGAGGAGGAGGA SARS-CoV 2 2020-03-01 USA:IL MI304482 28840 TATCGCALCAGTY ALGALANT ALCICLAGGCALGETA GAN TITLCCTGCTGCALAGTGGCGGGGGGGGAGGGAGGAGGAGGA GAL TITLCCTGCTGCALAGGGCGALGGGAGGGAGGAGGA GAL TITLCCTGCTGCALAGGGCGALGGGAGGGAGGAGGAGGA GAL TITLCCTGCTGCALAGGGCGALGGAGGAGGAGGA GAL TITLCCTGCTGCALAGGGCGALGGGAGGGAGGAGGAGGA GAL TITLCCTGCTGCALAGGAGGGAGGGAGGAGGAGGAGGAGGAGGAGGAGGAGG									
 SARS-Cov 2 2020-01-21 USA:IL MI909713 28940 TASTCSCAACASTT AAGAAATT AACTCCAGGCAGCAGTA GAA TTTCTCTGCTAGAATGGCTGCCAATGGCGGGGGGGGGG			And a second s		28870	28880	28890	28900	
SARS-Cov 2 2020-01-28 USA:LL MT0442572840INSTCGCAACAGTTAAGATCAAGGCACCAGTAGAATITCTCTCTGCTAGAATGCTGCCAATGCCGGCGSARS-Cov 2 2020-03-01 USA:LL MT30448228840IAGTCGCAACAGTTAAGTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGCGGCGSARS-Cov 2 2020-03-13 USA:LL MT30448228840IAGTCGCAACAGTTAAGTAAATAACTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGCGGCGGGGSARS-Cov 2 2020-03-13 USA:LL MT2634232890IAGTCGCAACAGTTAAGAAATAACTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGCGGGGSARS-Cov 2 2020-03-13 USA:LL MT2634332890IAGTCGCAACAGTAAGAAATAACTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGCGGGSARS-Cov 2 2020-03-20 USA:LM MT304482890IAGTCGCAACAGTAAGAAATAACTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGCGGGSARS-Cov 2 2020-03-20 Spain:Valencia MT232572890IAGTCGCAACAGTAAGAAATAACTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-09 Spain:Valencia MT2925792876IAGTCGCAACAGTAAGAAATTAACTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGGGSARS-Cov 2 2020-03-09 Spain:Valencia MT2925792876IAGTCGCAACAGTAAGAAATTAACTCCAGGCACCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-01 Spain:Valencia MT292572876IAGTCGCAACAGTAAGAAATTAACTCCAGGCACAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-10 Spain:Valencia MT292572876IAGTCGCAACAGTAAGAAATTAACTCCAGGCACAGTAGAATITCTCTGCTA					AACTCCAGGCAGCAG	TABBBGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-01 USA:1L MT3044822840INSTCEGAACAGTAACTCCAGGCACCAGTAGAATITCTCTCTGCTAGAATGGCTGCCAATGGCGGCGGGGSARS-CoV 2 2020-03-13 USA:1L MT2634292802TAGTCGCAACAGTTAAGTACCAGGCAGCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-13 USA:1L MT2634292802TAGTCGCAACAGTTAAGTACCAGGCAGCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-13 USA:1L MT2634292800TAGTCGCAACAGTTAAGTAATTAACTCCAGGCAGCAGTAGAATITCTCTGCTAGAATGGCTGGCAATGGCGGGGGGGGGGGG			TAGTCGCAACAGTT	YAAGAAATT	AACTCCAGGCAGCAG	TAGGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA.
SARS-Cov 2 2020-03-01 USA:IL MT3044832840INSTECCAACAGTTAAGRAATTAACTCCASGCAGCAGTAGAASARS-Cov 2 2020-03-13 USA:IL MT2634292871IASTCCAACAGTTAACTCCAGCAGCAGTAGAATICTCCTCCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-13 USA:IL MT26343228716IASTCCGACAGTTAACTCCAGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-10 USA:IL MT26343228809IASTCCGACAGTAAACTCCAGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-04 USA:IV MT3046028809IAGTCGCACAGTAAACTCCAGCGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-04 USA:IV MT325072880IAGTCGCACAGTAAACTCCAGCGCAGCAGTAGAATICTCCTGCTAGATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-09 Spain:Valencia MT292572876IAGTCGCACAGTAAAGAATTAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-09 Spain:Valencia MT292572876IAGTCGCAACAGTAAAGAATTAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-10 Spain:Valencia MT292572876IAGTCGCAACAGTAAAGAATTAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-10 Spain:Valencia MT292572876IAGTCGCAACAGTAAAGAATTAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-10 Spain:Valencia MT292572876IAGTCGCAACAGTAAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-Cov 2 2020-03-10 Spain:Valencia MT292572876IAGTCGCAACAGTA </th <th></th> <th></th> <th>TAGTCGCAACAGTT</th> <th>AAGAAATT</th> <th>AACTCCAGGCAGCAG</th> <th>TA GAA</th> <th>TTCTCCTGC</th> <th>TAGAATGGCT</th> <th>GGCAATGGCGGTGA</th>			TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TA GAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-13 USA:IL MT26342928827TAGTOGCAACAGTTI AAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-13 USA:IL MT26342828910TAGTCGAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-02 USA:IN MT30446828940TAGTCGAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-04 USA:IN MT3250228940TAGTCGCAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-02 USA:IN MT325022876TAGTCGCAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGSARS-CoV 2 2020-03-09 Spain:Valencia MT292572876TAGTCGCAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGSARS-CoV 2 2020-03-09 Spain:Valencia MT292572876TAGTCGCAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-10 Spain:Valencia MT292572876TAGTCGCAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-10 Spain:Valencia MT292572876TAGTCGCAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-10 Spain:Valencia MT292572876TAGTCGCAACAGTTAAGAAATTAACTOCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-10 Spain:Valencia MT292572876TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCA			TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TASSGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-13 USA:IL MT26342828716TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-13 USA:IL MT2634332809TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-02 USA:IW MT3046122840TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGGSARS-CoV 2 2020-03-02 Spain:Valencia MT292572840TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGGSARS-CoV 2 2020-03-02 Spain:Valencia MT292572876TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-09 Spain:Valencia MT292572876TAGTOGCAACAGTTAAGAAATTTACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-09 Spain:Valencia MT292572876TAGTOGCAACAGTTAAGAAATTTACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-10 Spain:Valencia MT292572876TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-10 Spain:Valencia MT292572876TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-15 Spain MT398662887TAGTOGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGSARS-CoV 2 2020-03-15 Spain MT398662880TAGTOGCAACAGTTAAGAAATTAACTCCA			TAGICGCAACAGII	AAGAAAII	AACICCAGGCAGCAG	TASSGAA		TAGAATGGCT	GGCAAIGGCGGIGA.
SARS-Cov 2 2020-03-13 USA:II MT26343328809TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-Cov 2 2020-03-02 USA:IV MT30446628840TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-Cov 2 2020-03-02 USA:IV MT304466TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-Cov 2 2020-03-02 Spain:Valencia MT23351928766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-Cov 2 2020-03-09 Spain:Valencia MT2925728766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-09 Spain:Valencia MT29257128766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-09 Spain:Valencia MT29257128766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-15 Spain MT3598662880TAGTGCCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-15 Spain MT3598662880TAGTGCCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-Cov 2 2020-03-15 Spain MT3598662880TAGTGCCAACAGTTAAGAATTAACTCCAGGCAGCA			TAGICGCAACAGII.	AAGAAAII	AACICCAGGCAGCAG	TACCOGAA		TAGAATGGCT	GGCAAIGGCGGIGA.
SARS-CoV 2 2020-03-02 USA:NY MT304486 28840 TAGTGGCAACAGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-04 USA:NY MT32527 28840 TAGTGGCAACAGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-02 Spain:Valencia MT32527 2876 TAGTGGCAACAGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-09 Spain:Valencia MT29257 2876 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-09 Spain:Valencia MT29257 2876 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-09 Spain:Valencia MT29257 2876 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-10 Spain:Valencia MT29257 2876 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-10 Spain:Valencia MT29257 2876 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-10 Spain:Valencia MT29257 2876 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTG SARS-CoV 2 2020-03-15 Spain MT359865 28827 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCAATGGCGGTGG SARS-CoV 2 2020-03-15 Spain MT359865 28827 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCAATGGCGGGGG SARS-CoV 2 2020-03-15 Spain MT359865 28827 TAGTGGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-13 Taly MT06615 2840 TAGTGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-13 Taly MT06615 2840 TAGTGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-13 Taly MT06615 2840 TAGTGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-18 Ceeh Republik MT37157 2878 TAGTGCAACGTT AAGAATT AACTCCAGGCAGCAFA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-COV 2 2020-03-18 Ceeh Republik MT37157 2873 TAGTGCAACGTT AAGAATT AACTCCAGGCAGCAFAACGAA TTCTCCTGCT			TAGICGCAACAGII	AAGAAATT	AACICCAGGCAGCAG	TACCOGAA		TAGAATGGCT	GGCAAIGGCGGIGA.
SARS-CoV 2 2020-03-04 USA:NY MT32562728840TAGTCGCAACAGTTAAGAATTDACTCCAGGCAGCATAGAASARS-CoV 2 2020-02-27 Spain:Valencia MT23351928786TAGTCGCAACAGTTAAGAATTDACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257928786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257928786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257128786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT35986528827TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT35986528837TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT35986528837TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-16 Tayain MT35986528837TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-16 Tayain MT35986528837TAGTCGCAACAGTTA			TAGICGCAACAGII	AAGAAAII	AACICCAGGCAGCAG	TACCCGAA		TAGAAIGGUI	GGCAAIGGCGGIGA.
SARS-CoV 2 2020-02-27 Spain:Valencia MT23351928766TAGTCGCAACAGTTAAGAATTTAGTCCAGGCAGCATAGAASARS-CoV 2 2020-03-02 Spain:Valencia MT29257428766TAGTCGCAACAGTTAAGAATTTAGTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257128766TAGTCGCAACAGTTAAGAATTAAGTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257128766TAGTCGCAACAGTTAAGAATTAAGTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACAGTTAAGAATTAAGTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-15 Spain MT35986528870TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-01-30 Taly MT061562880TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-01-30 Taly MT0771252876TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGSARS-CoV 2 2020-02-07 Sweden MT0935712880TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-18 Czeh Republik MT3715742873TAGTGCCAACAGTTAAGAATTAACTCCAGGCAGCAGTA <td< th=""><th></th><th></th><th>TAGICGCAACAGII</th><th>AAGAAATT</th><th>AACICCAGGCAGCAG</th><th>TACCOGAA</th><th></th><th>TAGAAIGGUI</th><th>GGCAAIGGCGGIGA.</th></td<>			TAGICGCAACAGII	AAGAAATT	AACICCAGGCAGCAG	TACCOGAA		TAGAAIGGUI	GGCAAIGGCGGIGA.
SARS-CoV 2 2020-03-02 Spain:Valencia MT29257428766TAGTGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCTGCTAGAATGGCTGGCAATGGCGTGGSARS-CoV 2 2020-03-09 Spain:Valencia MT29257028766TAGTGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGTGGSARS-CoV 2 2020-03-09 Spain:Valencia MT29257028766TAGTGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-10 Spain:Valencia MT29257028766TAGTGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-10 Spain:Valencia MT29257028766TAGTGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-10 Spain:Valencia MT2925702876TAGTGCGAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-10 Spain:Valencia MT2925702876TAGTGCGAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-15 Spain MT3598662880TAGTGCGAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-01-30 Italy MT061562880TAGTGCGAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCAGCGTGGCAATGGCGGTGGSARS-CoV 2 2020-03-17 Steam MT3905712876TAGTGCGAACAGTTAAGAATTAACTCCAGGCAGCAATAGAATTCTCCTGCTAGAATGGCAGCGGTGGCAATGGCGGTGGSARS-CoV 2 2020-03-18 Czeh Republik MT37157028732TAGTGCGAACAGTTAAGAATTAACTC			TAGICGCAACAGII	AAGAAATT	TAACICCAGGCAGCAG	TACCORA		TAGAALGGUI	CCCARIGGCGGIGA.
SARS-CoV 2 2020-03-09 Spain:Valencia MT29256928786TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257128786TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257028786TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT35986528827TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT35986528830TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-013-15 Spain MT35986628830TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-013-15 Spain MT35986628830TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-013-11 Italy MT071252874TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-013-11 Italy MT071252874TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-02-07 Sweden MT0935712874TAGTCGCAACAGTTAAGAANTTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-18 Czeh Republik MT3715702872TAGTCGCAACAGTTAA			TAGICGCAACAGII	AAGAAATT.	TAACICCAGGCAGCAG	TACCAR	TTCTCCTCC	TAGAAIGGCI	COCANTOCCOUTCA
SARS-CoV 2 2020-03-09 Spain:Valencia MT2925712876TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-09 Spain:Valencia MT2925722876TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT2925722876TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT2925722876TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT2925722876TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT3598652880TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT3598662880TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT3598662880TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-01-30 Italy MT061562880TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-02-07 Sweden MT0935712890TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-18 Czeh Republik MT3715742873TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-18 Czeh Republik MT3715742873TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCATAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-18 Czeh Republik MT37157			TAGICGCAACAGII	AAGAAATT	AACICCAGGCAGCAG	TACCORA	TTCTCCTCC	TAGAAIGGCI	COCANTOCCOTON
SARS-CoV 2 2020-03-09 Spain:Valencia MT29257028766TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257028766TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-10 Spain:Valencia MT29257028766TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-10 Spain:Valencia MT2925702876TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-15 Spain MT35986628827TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-01-30 Italy MT0661562880TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-01-30 Italy MT071252874TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-01-31 Italy MT071252874TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-01-31 Italy MT071252874TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCAGCGGTGGCAATGGCGGTGGSARS-CoV 2 2020-03-17 Cxech Republik MT3715722874TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-18 Cxech Republik MT37157128732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGC			TAGICGCAACAGII	AAGAAATT	AACICCAGGCAGCAG	TASSOGAA	TTCTCCTGC	TAGAAIGGCI	GCCANTGGCGGIGA.
SARS-CoV 2 2020-03-10 Spain:Valencia MT29257028766TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257228766TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT35986528827TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-03-15 Spain MT35986628830TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-01-31 Italy MT0615628840TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-01-31 Italy MT07712528740TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-01-31 Italy MT07712528740TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-01-31 Italy MT07712528740TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCATAGAASARS-CoV 2 2020-01-31 Italy MT07712528740TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT07712528740TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT07712528740TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT07157028730TAGTCGCAACCAGTTAAGAAATT			TAGICGCAACAGII	AAGAAATT	TAACICCAGGCAGCAG	TABBBBBAA	TTCTCCTGC	TAGAAIGGCI	GCCANTGGCGGIGA
SARS-CoV 2 2020-03-10 Spain:Valencia MT29257228786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-10 Spain:Valencia MT29257528786TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-15 Spain MT35986528830TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-15 Spain MT35986528830TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-30 Italy MT0615628840TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-30 Italy MT07712528740TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-02-07 Sweden MT09357128840TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-18 Cech Republik MT37157428730TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-17 Cech Republik MT37157428732TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-18 Cech Republik MT37157428732TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAAACGAAGAASARS-CoV 2 2020-03-18 Cech Republik MT37157228732TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAAACGAAGAASARS-CoV 2 2020-03-18 Cech Republik MT37157228732TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGCAATGGCGGGGGGSARS-CoV 2 2020-03-18 Cech Republik MT37157228732TAGTCGCAACAGTTAAGAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGG <t< th=""><th></th><th></th><th>TAGICGCAACAGII</th><th>AAGAAATT</th><th>AACTCCAGGCAGCAG</th><th>TACCAA</th><th>TTCTCCTGC</th><th>TAGAATGGCI</th><th>GCANTGCCGGIGA</th></t<>			TAGICGCAACAGII	AAGAAATT	AACTCCAGGCAGCAG	TACCAA	TTCTCCTGC	TAGAATGGCI	GCANTGCCGGIGA
SARS-CoV 2 2020-03-10 Spain:Valencia MT29257528766TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-15 Spain MT35986528827TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-15 Spain MT35986628827TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-30 Italy MT06615628840TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT0712528740TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT0712528740TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-01-31 Italy MT0712528740TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-19 Kweden MT03057128400TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGS-CoV 2 2020-03-17 Czech Republik MT37157328732TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-18 Czech Republik MT37157128732TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-19 Czech Republik MT37157228732TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATICTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-19 Czech Republik MT37157228732TAGTGCGAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATICTCCTGCTAGAATGGCG			TAGTOGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TASSOCAA	TTCTCCTGC	TAGAATGGCT	GCCANTGGCGGTGA
SARS-CoV 2 2020-03-15 Spain MT35986528827TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-15 Spain MT35986628830TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT0615628840TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT07712528764TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT07712528764TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-02-07 Sweden MT09357128840TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-17 Czech Republik MT37157328783TAGTGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-18 Czeh Republik MT37157428732TAGTGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-18 Czeh Republik MT37157428732TAGTGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGSARS-CoV 2 2020-03-19 Czeh Republik MT37157228732TAGTGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGSARS-CoV 2 2020-03-19 Czeh Republik MT37157228732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGGSARS-CoV 2 2020-03-19 Czeh Republik MT37157228732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGGSARS-CoV 2 2020-03-19 Czeh Republik MT371572 <th></th> <th></th> <th>TAGTCGCAACAGTT</th> <th>AAGAAATT</th> <th>AACICCAGGCAGCAG</th> <th>TACCORA</th> <th>TTCTCCTGC</th> <th>TAGAATGGCT</th> <th>GCANTGCCGTCN</th>			TAGTCGCAACAGTT	AAGAAATT	AACICCAGGCAGCAG	TACCORA	TTCTCCTGC	TAGAATGGCT	GCANTGCCGTCN
SARS-CoV 2 2020-03-15 Spain MT35986628830TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCATAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-01-30 Italy MT0615628940TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAACGAAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-01-31 Italy MT071252874TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAACGAAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-02-07 Sweden MT0935712840TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAACGAAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-17 Czech Republik MT37157328732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-18 Czech Republik MT37157328732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-18 Czech Republik MT37157228732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-19 Czech Republik MT37157228732TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-19 Czech Republik MT37157228732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-19 Czech Republik MT37157228732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCAGGCAGGCGGGGSARS-CoV 2 2020-03-19 Czech Republik MT37157028732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGAAATGAAA			TAGTOGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TASSEGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-01-30 Italy MT06615628840TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT0712528784TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-01-31 Italy MT0712528784TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-02-07 Sweden MT032057128840TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03 France MT32053828840TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAGAAS-CoV 2 2020-04-24 Netherlands:Milheeze MT3962662830TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03-17 Czech Republik MT37157328732TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-18 Czech Republik MT37157428732TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-18 Czech Republik MT37157228732TAGTCGCAACCAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGSARS-CoV 2 2020-03-19 Czech Republik MT37157228732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGSARS-CoV 2 2020-03-19 Czech Republik MT37157028732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGSARS-CoV 2 2020-03-19 Czech Republik MT37157028732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG <t< th=""><th></th><th></th><th>TAGTOGCAACAGTT</th><th>AAGAAATT</th><th>AACTCCAGGCAGCAG</th><th>TAAACGAA</th><th>TTCTCCTGC</th><th>TAGAATGGCT</th><th>GGCAATGGCGGTGA</th></t<>			TAGTOGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAACGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-01-31 Italy MT077125 28764 TAGTGCGAACAGTT AAGAANT AACTCCAGGCAGCATA GAA SARS-CoV 2 2020-02-07 Sweden MT093571 28840 TAGTGCGACCAGTT AAGAANT AACTCCAGGCAGCATA GAA SARS-CoV 2 2020-02-07 Sweden MT093571 28840 TAGTGCGACCAGTT AAGAANT AACTCCAGGCAGCATA GAA TCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-70 Sweden MT093571 28830 TAGTGCGACCAGTT AAGAANT AACTCCAGGCAGCATA GAA TCTCCTGCTAGAATGGCTGGCAATGGCGGTGG S-CoV 2 2020-03-17 Czech Republik MT371571 28732 TAGTGCGAACAGTT AAGAANT AACTCCAGGCAGCATAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGG SARS-CoV 2 2020-03-18 Czeh Republik MT371571 28732 TAGTGCGAACAGTT AAGAANT AACTCCAGGCAGCATAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGGGGGGG SARS-CoV 2 2020-03-18 Czeh Republik MT371571 28732 TAGTGCGAACAGTT AAGAANT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGCAATGGCGGGGGGG SARS-CoV 2 2020-03-19 Czeh Republik MT371572 28732 TAGTGCGAACAGTT AAGAANT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGCAATGGCGGCGGGGG SARS-CoV 2 2020-03-19 Czeh Republik MT371572 28732 TAGTGCGAACAGTT AAGAANT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGC			TAGTOGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TABBBBBB	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-02-07 Sweden MT09357128840TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAASARS-CoV 2 2020-03 France MT30235828840TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAAS-CoV 2 2020-03-17 Czech Republik MT37157328732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-17 Czech Republik MT37157328732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAACGAAGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-18 Czech Republik MT37157128732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-19 Czech Republik MT37157028732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-21 Czech Republik MT37157028732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCTGGCAATGGCGGTGGSARS-CoV 2 2020-03-22 Czech Republik MT37157028732TAGTCGCAACAGTTAAGAAATTAACTCCAGGCAGCAGTAAACGAATTCTCCTGCTAGAATGGCAGCGGCGGGAGAACGAGTAAACGAA			TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
S-CoV 2 2020-04-24 Netherlands:Milheeze MT396266 28830 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTA_GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-17 Czech Republik MT371571 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-18 Czech Republik MT371571 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-18 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACGATT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACGATT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-COV 2 2020-03-18 Greec MT328032 2840 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG			TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
S-CoV 2 2020-04-24 Netherlands:Milheeze MT396266 28830 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTA_GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-17 Czech Republik MT371571 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-18 Czech Republik MT371571 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-18 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACGATT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACGATT AAGAATT AACTCCAGGCAGCAGTAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-COV 2 2020-03-18 Greec MT328032 2840 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG	SARS-CoV 2 2020-03 France MT320538	28840	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-18 Czech Republic MT371574 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-18 Czech Republik MT371571 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-19 Czech Republik MT371572 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGAA TTCTCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371578 28716 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGAA TTCTCTGCTAGAATGGCTGGCAATGGCGGGGGG SARS-CoV 2 2020-03-18 Greece MT328032 28401 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGTAAACGAA TTCTCTGCTAGAATGGCTGGCAATGGCGGGGGGGGGGGG			TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TACCOGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-18 Czech Republic MT371574 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-18 Czech Republik MT371571 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-19 Czech Republik MT371572 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCATAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGAA TTCTCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-21 Czech Republik MT371578 28716 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGAA TTCTCTGCTAGAATGGCTGGCAATGGCGGGGGG SARS-CoV 2 2020-03-18 Greece MT328032 28401 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGTAAACGAA TTCTCTGCTAGAATGGCTGGCAATGGCGGGGGGGGGGGG	SARS-CoV 2 2020-03-17 Czech Republik MT371573	28732	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAACGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-19 Czech Republik MT371569 28766 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TICTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-19 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TICTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TICTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-21 Czech Republik MT371576 28732 TAGTGCGAACAGTT AAGAAATT AACTCCAGGCAGCGATAAACGAA TICTCCTGCTAGAATGGCTGGCGATGGCGGTGG SARS-CoV 2 2020-03-18 Greece MT328032 28840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TICTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-18 Greece MT328032 28840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TICTCCTGCTAGAATGGCTGGCAATGGCGGGGG		28732	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAACGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-19 Czech Republik MT371572 28732 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCGGCGGCAGTGGCAGTGGCAGTGGCGGTGG SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCATGGCGGTGG SARS-CoV 2 2020-03-22 Czech Republik MT371568 28716 TAGTCGCAACAGTT AAGAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG SARS-CoV 2 2020-03-18 Greece MT328032 2840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGG	SARS-CoV 2 2020-03-18 Czech Republik MT371571	28732	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAACGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-21 Czech Republik MT371570 28732 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCGGCGGCAGTGGCAGTGGC SARS-CoV 2 2020-03-22 Czech Republik MT371568 28716 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG SARS-CoV 2 2020-03-18 Greece MT328032 28840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG	SARS-CoV 2 2020-03-19 Czech Republik MT371569	28766	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAACGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-22 Czech Republik MT371568 28716 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCGGCGAGTGGCGGCAGTGGCAGTGGCGGCAGTGGCGGCAGTGGCGGCAGTGGCGGCAGTGGCGGGGGGGG	SARS-CoV 2 2020-03-19 Czech Republik MT371572	28732	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAAC <mark>GAA</mark>	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-18 Greece MT328032 28840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGG	SARS-CoV 2 2020-03-21 Czech Republik MT371570	28732	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAACGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
	SARS-CoV 2 2020-03-22 Czech Republik MT371568	28716	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAACGAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
	SARS-CoV 2 2020-03-18 Greece MT328032	28840	TAGTOGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAAC <mark>GAA</mark>	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-18 Greece MT328033 28840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGTGA	SARS-CoV 2 2020-03-18 Greece MT328033	28840	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAAC <mark>GAA</mark>	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-18 Greece MT328034 28840 TAGTCGCAACAGTT AAGAAATTTAACTCCAGGCAGCAGTA GAA TTCTCCCTGCTAGAATGGCTGGCAATGGCCGGCGG		28840	TAGTCGCAACAGTT	AAGAAATT	T <mark>AACTCCAGGCAGCAG</mark>	TA <mark>GGG</mark> GAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
SARS-CoV 2 2020-03-18 Greece MT328035 28840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAATTTCTCCCCGCCAGAATGGCCGGCAGCAGGA		28840	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TA <mark>AAC</mark> GAA	TTTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
S-CoV 2 2020-03-14 Germany: Düsseldorf MT394864 28786 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTA GAA TTCTCCTGCTAGAATGGCTGGCAATGGCGGGGG			TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TA <mark>BBB</mark> GAA	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA
RS-CoV 2 2020-03-19 Germany: Hamburg MT318827 28840 TAGTCGCAACAGTT AAGAAATT AACTCCAGGCAGCAGTAAACGAA TTCCCCGGCTAGAATGGCTGGCAATGGCCGGCGG	RS-CoV 2 2020-03-19 Germany: Hamburg MT318827	28840	TAGTCGCAACAGTT	AAGAAATT	AACTCCAGGCAGCAG	TAAAC <mark>GAA</mark>	TTCTCCTGC	TAGAATGGCT	GGCAATGGCGGTGA

Fig. 1. Visual example of the analytical method used in mutant evaluation. Screenshot of the 28,840 nucleotide (nt.)-28,920 nt. segment from the SARS-CoV-2 nucleotide sequence of different samples from Europe and the US. DNA sequences were aligned with the GGG \rightarrow AAC mutation at position 28,881 nt. For DNA alignments the program Vector NTI Advance 11.0 Tool Align X was used. The top row presents the sequence of the original 2019 Wuhan, China isolate (NC_045512.2) which served as the reference for all sequence comparisons.

Table 1 Synopsis of Data.

Genome Position	Mutation	China	Europe	Germany	Munich*	USA I	USA II	India
241nt	$CG \rightarrow TG$	0/98	80/99	4/62	14/14	76/111	74/96	82/99
1,059nt	$CC \rightarrow TC$	0/99	5/99	21/62	0/14	42/111	45/97	0/99
1,440nt	$GC \rightarrow AC$	0/99	0/99	15/62	0/14	3/112	0/97	0/99
1,917 nt	$CT \rightarrow TT$	0/99	0/99	0/62	0/14	0/112	11/97	0/99
2,891nt	$GC \rightarrow AC$	0/99	0/99	15/62	0/14	3/112	0/97	0/99
3,037nt	$CT \rightarrow TT$	2/99	80/99	41/62	14/14	75/111	72/97	81/99
6,446nt	$GT \rightarrow AT$	0/99	0/99	0/62	10/14	0/112	1/97	0/99
8,782nt	$CC \rightarrow TC$	29/99	5/99	1/62	0/14	15/112	15/97	7/99
14,408nt	$CT \rightarrow TT$	2/99	81/99	39/62	0/14	78/112	71/97	80/99
17,747nt	$CT \rightarrow TT$	0/99	0/99	0/62	0/14	8/112	12/97	0/99
17,858nt	$AT \rightarrow GT$	0/99	0/99	0/62	0/14	8/112	12/97	0/99
18,060nt	$CT \rightarrow TT$	0/99	0/99	0/62	0/14	9/112	11/97	0/99
22,444nt	$CC \rightarrow TC$	0/99	0/99	0/62	0/14	0/112	1/97	26/99
23,403nt	$AT \rightarrow GT$	0/99	81/99	1/62	14/14	77/112	72/97	80/99
25,563nt	$GA \rightarrow TA$	0/99	7/99	21/62	0/14	65/112	54/97	43/99
26,735nt	$CA \rightarrow TA$	0/99	1/99	0/62	0/14	0/112	1/97	39/99
28,144nt	$TA \rightarrow CA$	29/99	5/99	1/62	0/14	15/112	15/97	7/99
28,854nt	$CA \rightarrow TA$	2/99	0/99	1/62	0/14	3/112	3/97	29/99
28,881nt	$GGG \rightarrow AAC$	2/99	35/99	9/62	0/14	3/112	6/97	2/99

Survey of all sequence comparisons of hotspot mutations. Synopsis of the most frequent SARS-CoV-2 mutations collected from 570 nucleotide sequences of NCBI GenBank sequences from China, Europe, Germany, *Munich, the US (I and II), and India. Hotspot mutations (highlighted by enhanced print) arose, as SARS-CoV-2 expanded from China to different countries and populations. The * relates to the work by Böhmer et al., 2020 who followed 16 COVID-19 patients from the Munich, Germany area, but SARS-CoV-2 sequence data were published for only 14. CORRECTION: Please use enhanced print of numbers as used in Table 1 of the original manuscript. Many thanks.

3.2. Europe

Table S2 presents analyses of 99 nucleotide sequences in SARS-CoV-2 isolates from European countries (Czech Republic, Finland, France, Greece, Italy, Netherlands, Poland, Serbia, Spain, and Sweden).

Compared to the Wuhan reference sequence, five signal hotspot mutations were noted in positions 241 (CG \rightarrow TG, 80/99), 3,037 (CT \rightarrow TT, 80/99), 14,408 (CT \rightarrow TT, 81/99), 23,403 (AT \rightarrow GT, 81/99), and 28,881 (GGG \rightarrow AAC, 35/99). In positions 8,072 (5/99), 8,782 (5/99), 9,477 (5/99), 11,083 (8/99), 14,805 (8/99), 20,268 (9/99), 25,563 (7/ 99), 26,144 (7/99), 28,144 (5/99) and others, mutations were also found, though much less frequently.

The mutation in position 28,881 comprised three nucleotides, GGG to AAC in 35/98 of the analyzed sequences. This mutation affected the open reading frame for the nucleocapsid phosphoprotein N, altered the original sequence AGG GGA to AAA CGA (see Table 2), and led to a change in amino acid sequence positions 50 and 51 from Arg-Gly (RG) to Lys-Arg (KR) and thus juxtaposed two very polar basic amino acids.

3.3. Germany

Possibly due to the strictly implemented lockdown early in the pandemic and by good luck, this country has so-far been spared excessive fatalities, although more recently (September 2020) there has been an increasing number of COVID-19 cases. It is solely for this reason that search results from 62 different isolates from Germany (Table S3) have been listed separately from samples from other European countries. Some of the previously identified mutation hotspots were confirmed at nucleotide numbers 1,059 (21/62), 3,037 (41/62), 14,408 (39/62), 25,563 (21/62), and 28,881 (9/62). There were two additional hotspot mutations in positions 1,440 (GC \rightarrow AC, 15/62) and 2,891 (GC \rightarrow AC, 15/62). In positions 241 and 23,403, the high mutation rates in samples from Europe (Table S2) were not observed in the samples from Germany.

In this context, it will be interesting to compare the results from the published Munich study (Böhmer et al., 2020), in which sequences of 14 isolates from patients were described. They had contracted COVID-19 in January 2020, and their SARS-CoV-2 infection could reportedly be tracked to a single conference attendee from China in the Munich area. In the Munich patient cohort, only sequence positions 241 (14/14), 3, 037 (14/14), and 23,403 (14/14) showed high mutation frequencies, whereas others failed to be represented (data included in synopsis

Table 2

Codon Changes SARS-CoV-2.

Genome Position	DNA Sequence Original → Mutation	Amino Acid Original → Mutation	$ORF \rightarrow Product$
1,059nt	$\text{CC} \rightarrow \text{TC}$	ACC (Threonine) \rightarrow	ORF1ab mature
		ATC (Isoleucine)	peptide \rightarrow nsp 2
1,440nt	$GC \rightarrow AC$	$GGC (Glycine) \rightarrow GAC$	ORF1ab mature
1.017	OT TT	(Aspartic Acid)	peptide \rightarrow nsp 2
1,917 nt	$CT \rightarrow TT$	ACT (Threonine) \rightarrow	ORF1ab mature
2,891nt	$GC \rightarrow AC$	ATT (Isoleucine) GCA (Alanine) \rightarrow ACA	peptide → nsp 2 ORF1ab mature
2,091111	$GC \rightarrow AC$	$(Threonine) \rightarrow ACA$	peptide \rightarrow nsp 3
6,446nt*	$GT \rightarrow AT$	(THEOHINE) GTT (Valine) \rightarrow ATT	$ORF1ab \rightarrow ORF1ab$
0,440111	$01 \rightarrow m$	(Isoleucine) $\rightarrow RTT$	polyprotein segment 1
14,408nt	$CT \rightarrow TT$	CCT (Proline) \rightarrow CTT	$ORF1ab \rightarrow ORF1ab$
.,		(Leucine)	polyprotein segment 2
17,747nt	$CT \rightarrow TT$	CCT (Proline) \rightarrow CTT	ORF1ab mature
		(Leucine)	peptide \rightarrow helicase
17,858nt	$AT \rightarrow GT$	TAT (Tyrosine) \rightarrow TGT	ORF1ab mature
		(Cysteine)	peptide \rightarrow helicase
23,403nt	$AT \rightarrow GT$	GAT (Aspartic Acid) \rightarrow	Surface glycoprotein
		GGT (Glycine)	
28,144nt	$TA \rightarrow CA$	TTA (Leucine) \rightarrow TCA	$ORF8 \rightarrow ORF8$ protein
		(Serine)	
28,854nt	$CA \rightarrow TA$	TCA (Serine) \rightarrow TTA	Nucleocapsid
		(Leucine)	phosphoprotein
28,881nt	$GGG \rightarrow AAC$	$AGGGGA \rightarrow AAACGA$	Nucleocapsid
		(Arginine Glycine) (Lysine Arginine)	phosphoprotein
		(Lysine Arginne)	

Coding changes in mutants. A listing of amino acid exchanges due to the SARS-CoV-2 RNA mutations with the highest frequencies. The reading frames (proteins) affected were also listed. Amino acid sequence-neutral mutations have not been included. The latter mutations might still have altered the structure of the SARS-CoV-2 RNA and affected its ability to bind to or interact with cellular and viral proteins. The * relates to the publication by Böhmer et al., 2020. The mutation in position 23,403 has been investigated by Korber et al. (2020) for its potential to enhance viral infectivity. Table 1). Moreover, position 6,446 presented with a mutation frequency of 10/14 which did not register in samples from China or any other country. In the samples from China chosen for our analyses (Table S1), the high frequency mutations from the Munich study were altogether absent or (at nucleotide 3,037) present at a low frequency of 2/99. Notably, the mutation in position 28,881 was absent from the Munich list, although it was found at 2/99 in the samples from China (Table S1). Of course, there might have been mutations in Chinese SARS-CoV-2 isolates not represented in the 99 sequences we analyzed (Table S1).

3.4. USA - I

The data on the analyses of 112 isolates from the US confirmed the steady rise in mutation frequencies as SARS-CoV-2 spread to different parts of the world (Table S4). These samples from the US were collected before the more recent (June/July 2020) recurrence of COVID-19 in several parts of the US (Table S4). Some of the mutations annotated in Tables S1 (China) and S2 (Europe) were found even more frequently in this US cohort, like in SARS-CoV-2 nucleotide positions 241 (CG \rightarrow TG, 76/111), 1,059 (CC→TC, 42/112), 3,037 (CT→TT, 75/112), 8,782 (CC→TC, 15/112), 14,408 (CT→TT, 78/112), 18,877 (a new CT→TT transition, 13/112), 23,403 (AT-GT, 77/112), 25,563 (GA-TA, 65/ 112), 27,964 (CA→TA, 13/112, another new mutation), and 28,144 (TA \rightarrow CA, 15/112). The mutation in position 28,881 (GGG \rightarrow AAC, 3/112) was rarely seen. Hence, among the US samples 6 (plus 2 with only 15/ 112 representations) signal hotspot mutations stand out and their increased frequencies paralleled the intensity of viral replication after dissemination from China.

3.5. USA - II

The USA, unfortunately, has become the most severely SARS-CoV-2hit country in the world with 6.85 million COVID-19 cases and has tallied > 200,000 deaths (census September 23). We therefore analyzed an additional 97 SARS-CoV-2 RNA sequences from the most severely affected states Arizona (AZ), California (CA), Florida (FL) and Texas (TX) (Tables 1 and S5). The inspected sequences (Table S5) had been deposited between June 12 and July 07, 2020. The sequences discussed here had not been included in Table S4. In Table 1, the USA-I and USA-II analyses were juxtaposed and demonstrate that the previously identified hotspot mutations were still represented at about the same frequencies as shown in Table S4. The mutations at intermediate frequencies (12/ 97) in positions 17,747, 17,858, and 18,060 registered at frequencies between 8/112 and 9/112 at slightly lower frequencies in Table S4. We tested the hypothesis of differential distribution of mutation frequencies in the sequences from time point 1 (USA-I) and time point 2 (USA-II) using a permutation test as well as Kolmogorov-Smirnov test and failed to reject the null hypothesis of equivalent distributions, p > 0.6, suggesting that there is no significant difference in hotspot mutation frequencies between the two different time periods of sequence analyses from the US.

3.6. India

In Table S6, mutation analyses in nucleotide sequences of isolates from India have been summarized. Some of the hotspot mutations documented in isolates from the US were found in RNA samples from India as well, partly at increased frequencies, at sequence positions 241 (82/99), 3,037 (81/99), 14,408 (80/99), and 18,877 (45/99). In addition, there were high frequency mutations which were not observed on other continents: 22,444 (CC \rightarrow TC, 26/99), 23,403 (AT \rightarrow GT, 80/99), 25,563 (GA \rightarrow TA, 43/99), 26,735 (CA \rightarrow TA, 39/99), and 28,854 (CA \rightarrow TA, 29/99). In sequence positions 3,634 (CA \rightarrow TA, 8/99), 4,084 (CA \rightarrow TA, 12/99), 6,312 (CA \rightarrow TA, 10/99), 8,782 (CC \rightarrow TC, 7/99), 11,083 (GT \rightarrow TT, 13/99), 13,730 (CT \rightarrow TT, 9/99), 23,929 (CA \rightarrow TA, 10/99), and 28,311 (CC \rightarrow TC, 10/99) mutations with intermediated increases

were noted. In the samples studied here, the SARS-CoV-2 sequences from India showed the largest number (7) of hotspot mutations, which also had the highest occurrence (up to 82/99, i.e. 83 %) of mutation at a given nucleotide position (Table S6, Table 1).

As SARS-CoV-2 infections find susceptible populations around the world, and as the rate of viral replication shoots up in these populations, the number of new hotspots of mutation and the frequencies of mutations in individual hotspots were found increased. Permitting the virus to replicate with growing efficiency might render its genome better adapted and increasingly dangerous to human health. Alternatively, the possibility has to be considered that the lack of deleterious effects on the host and its tolerance might have favored the selection of mutants. Moreover, repeated bottlenecks in the replication of viruses have been shown in the case of vesicular stomatitis virus to reduce its fitness (so called Muller's ratchet) (Duarte et al., 1992). Lastly, accumulation of mutants during the worldwide spread of SARS-CoV-2 might eventually decrease its virulence. Hence, the consequences of an increase in the number of viral mutations on its pathogenicity will be very difficult to predict. Eventually, a possible decrease in virulence might turn out to set a limit to SARS-CoV-2's pandemic potential.

3.7. Russia

So far, we have inspected the available seven SARS-CoV-2 sequences from Russia and found mutation hotspots identical to the ones predominant in Europe (data not shown).

4. Discussion and conclusions

4.1. Nucleotide exchanges

Table 1 juxtaposes all hotspot mutations in isolates from different geographic regions. The majority of *de novo* mutation hotspots arose after SARS-CoV-2 had been transmitted to regions outside China and been allowed active replication in different environments (Tables S1 to S6). The mutations in positions 8,782 and 28,144 with frequencies 29/ 99 in sequences from China (Table S1) were found outside China only in the US I and II samples, though with moderate frequencies (15/97 or 15/112) and at even lower frequencies in the Indian samples (7/99) (Table 1). Hence most of the world-wide mutation hotspots described here (Tables S1 to S6) must have originated and been selected in the course of massive replication of SARS-CoV-2 in its worldwide expansion.

A challenging aspect arose from the identification of SARS-CoV-2 mutants in 14 COVID-19 patients from the Munich, Germany area in January 2020 (Böhmer et al., 2020). This report explained that a manufacturer of automobile parts in the vicinity of Munich was visited by a collaborator from China in January 2020. After the visitor had returned to China, she fell ill with Covid-19, and her contacts in the Munich area also came down with the disease. A comparison of the occurrence and frequencies of the mutants in positions 241, 3,037 and 23,403 in all 14 patients in the Munich report (Böhmer et al., 2020) to those in all other parts of the world (Table 1), does not render the Chinese traveler the most plausible source for SARS-CoV-2 in the Munich area. These very mutations, however, are frequent hotspots in Europe, Germany, the US (I and II) and India. Of course, it will have to be investigated whether the hotspot mutations apparent in the isolates from the Munich cohort might have been present, though infrequently, among Chinese isolates, in particular in the Munich visitor (patient 0) from China.

Mutations in sequence positions 3,037–14,408 - 23,403 or 25,563 occurred at low frequencies or were absent in samples from China, but expanded to levels up to 75/111 (68 %) and 81/99 (82 %) in the US and in India, respectively (Table 1). Increases in the number of hotspot mutations and the heightened percentage of sequences altered in a given hotspot in samples from Europe, and even more so from the US and India, suggested that these increases were tied to the intense replication

of SARS-CoV-2 in these countries upon its spreading from China in the course of just a few months. It will be interesting to investigate whether SARS-CoV-2 spreading to and massively replicating in constantly new, immunologically naïve populations furthers the selection of viral mutants, in particular of those with heightened pathogenicity.

The comparison of the number and frequency of hotspot mutations between samples from the USA I (34 States) (Table S4) and USA II (AZ, CA, FL, TX only) cohorts (Table S5) revealed no differences (Table 1), as corroborated by statistical analyses (see above).

In an earlier report (Pachetti et al., 2020), the authors analyzed 220 genomic sequences derived from patients infected by SARS-CoV-2 between December 2019 and mid-March 2020 and found eight mutations of SARS-CoV-2, located at positions 1,397, 2,891, 14,408, 17,746, 17, 857, 18,060, 23,403 and 28,881. These authors report mutations in positions 2,891, 3,036, 14,408, 23,403 and 28,881 to have been observed mainly in Europe, those at positions 17,746, 17,857 and 18, 060 in North America. Their results are interesting in that the mutations in sequence positions 1,397, 17,746, 17,857, and 18,060 did not show up in our analyses, whereas mutations in positions 2,891, 14,408, 23, 403, and 28,881 were found in our collection as well (Table 1). Since their sequence selection anteceded ours by several months, it is conceivable that the non-common mutations might have been counter-selected as the pandemic spread throughout the world. Of course, the less likely possibility existed that by chance their group and ours worked on non-overlapping sequences in the data bank. Furthermore, in a preprint deposit (Laamarti et al., 2020), the authors analyzed 3,067 SARS-CoV-2 genomes isolated from 59 countries during the first three months of the pandemic and found 716 site mutations distributed in six genes of the SARS-CoV-2 genome. These mutations belonged to certain genotypes which appeared to be specific to certain geographic regions.

4.2. Amino acid exchanges

Table 2 summarizes the amino acid exchanges due to sequence alterations in hotspot mutations identified in this study (Table 1). Mutations in sequence positions 241, 3,037, 8,782, 18,877, 22,444, 25,563, and 26,735 did not cause amino acid exchanges and were not included in Table 2. Aside from the possible functional and structural alterations in proteins altered by either codon-neutral or codon-affecting mutations, any mutation in SARS-CoV-2 RNA can impinge upon the structure of the single-stranded viral RNA molecule itself with consequences for important viral RNA-protein interactions.

In sequence position 28,881, the mutation AGG GGA \rightarrow AAA CGA changes the amino acid sequence of the nucleoprotein N in positions 50 and 51 from Arg-Gly (RG) to Lys-Arg (KR) (Table 2). The frequency of this mutation was found in isolates from different countries to be 2/99 (China), 35/99 (Europe), 9/62 (Germany), 3/112 (US I), 6/97 (US II) and 2/99 (India). The mutant amino acid sequence in nucleocapsid protein N between positions 29-35 (KKPRQKR) and 49-54 (RKRPEQ) (Table 2) raises questions about the possible generation of a nuclear localization signal (Kalderon et al., 1984) and strong DNA-binding motifs in protein N. For SARS-CoV-2 very little is known about activities in the nuclei of infected cells. One publication reports cell cycle-dependent nucleolar, not nuclear, localization of protein N, although for non-SARS coronaviruses (Cawood et al., 2007). It is presently unknown whether a mutated N protein might fundamentally alter the biology and pathogenicity of this SARS-CoV-2 mutant. It is also interesting to ponder how the Wuhan sequence in position 28,881 GGG was altered to AAC. Could RNA-RNA recombination have played a role?

Several of the mutants affect virus-encoded proteins with functions in the replication of SARS-CoV-2, like non-structural proteins (nsp 2, nsp 3) and the helicase. The important surface glycoprotein and the nucleocapsid phosphoprotein were also affected by codon changes. Evidence has been adduced that the D614G mutation of the SARS-CoV-2 spike protein bestows advantages on viral replication both in patients and in cell culture (Korber, 2020). In a preprint deposit (Isabel et al., 2020), this SARS-CoV-2 D614G spike protein mutation has also been described.

Among the 19 mutants listed in Table 1, 17 were transitions, 2 transversions, 12 led to amino acid changes in the proteins they were coding for, 7 were synonymous mutations. Of the transitions, 12 were C to T (U) mutations. So far, we have not detected any insertions or deletions in the sequences analyzed. A deletion in the SARS-CoV-2 genome with evolutionary implications has been recently described (Su et al., 2020).

It will now be important to correlate the identified hotspot mutations with the course and outcome of individual infections in humans. This demanding problem has not yet been tackled. Hopefully, the results of our study will provide a platform for those in SARS-CoV-2 research who take care of patients with SARS-CoV-2 infections. SARS-CoV-2 has the ability to mutate and, in its course of dissemination around the world, to select for distinct signal hotspot mutations depending on high rates of genome replication and complex environmental and genetic conditions in newly invaded territories. During its intercontinental journey, the exposure of SARS-CoV-2 to the 21st century's repertoire of medical resources may have been an additional selective force. The impact of an increase in hotspot SARS-CoV-2 mutations on immunogenesis and the prospects for vaccine development (Jackson et al., 2020) might be experienced and will have to be examined in the future.

Author contributions

S.W. carried out all work involving sequence selection and formal analyses, was involved in the conceptualization of the project and in the analysis and interpretation of data. C.R. analyzed data for their statistical significance. W.D. initiated the project, was involved in the conceptualization of the project and in the analysis and interpretation of data and wrote the manuscript.

Declaration of Competing Interest

The authors declare no competing interests.

Acknowledgments

We are grateful to Esteban Domingo, Universidad Autónoma de Madrid for alerting us to the Duarte et al. 1992 study. We thank Barbara Weiser and Harold Burger, University of California, Davis School of Medicine for critical comments on the manuscript. This research was funded by the Dr. Robert Pfleger Stiftung in Bamberg, Germany [5.12.2018]. W.D. is indebted to the Institute for Clinical and Molecular Virology of FAU in Erlangen, Germany for their continued hospitality extended to the Epigenetics Group.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.virusres.2020.198170.

References

- Böhmer, M., et al., 2020. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. Lancet Infect. Dis. 2020 (May 15) https://doi.org/10.1016/S1473-3099(20)30314-30315. S1473-3099(20) 30314-5.
- Cawood, R., Harrison, S.M., Dove, B.K., Reed, M.L., Hiscox, J.A., 2007. Cell cycle dependent nucleolar localization of the coronavirus nucleocapsid protein. Cell Cycle 6, 863–867.
- Coronavirus disease pandemic, 2020. Coronavirus disease (COVID-19) pandemic. World Health Organization, Geneva. https://www.who.int/emergencies/diseases/novel-co ronavirus-2019?gclid=EAIaIQobChMIi6qmo8jF6gIV9AiICR2T9w6sEAAYASAAEg KgovD BwE.
- Di Giorgio, S., et al., 2020. Evidence for host-dependent RNA editing in the transcriptome of Sars-CoV-2. Sci. Adv. 6 (2020) https://doi.org/10.1126/sciadv.abb5813.
- Duarte, E., Clarke, D., Moya, A., Domingo, E., Holland, J., 1992. Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proc. Natl. Acad. Sci. U.S.A. 89, 6015–6019.
- Fauci, S., Lane, H.C., Redfield, R.R., 2020. Covid-19 navigating the uncharted. Comment. N. Engl. J. Med. 382 (2020), 1268–1269.
- Hartenian, E., et al., 2020. The molecular virology of Coronaviruses [published online ahead of print, 2020 Jul 13]. J. Biol. Chem. 2020 https://doi.org/10.1074/jbc. REV120.013930 jbc.REV120.013930.
- Helmy, Y.A., et al., 2020. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J. Clin. Med. 9, 1225.
- Isabel, S., et al., 2020. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. bioRxiv. https://doi.org/10.1101/ 2020.06.08.140459 preprint This version posted June 8, 2020.
- Jackson, L.A., et al., 2020. An mRNA vaccine against SARS-CoV-2 preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2022483.
- Kalderon, D., Roberts, B.L., Richardson, W.D., Smith, A.E., 1984. A short amino acid sequence able to specify nuclear location. Cell 39, 499–509.
- et al, Korber, B., 2020. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827.
- Laamarti, M., et al., 2020. Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveal a clonal geo-distribution and a rich genetic variations of hotspot mutations. bioRxiv. https://doi.org/10.1101/2020.05.03.074567 preprint.
- Na, Zhu, et al., 2020. A novel coronavirus from patients with pneumonia in China 2019. N. Engl. J. Med. 382, 727–733.
- Pachetti, M., et al., 2020. Emerging SARS-CoV-2 mutation hot spots include a novel RNAdependent-RNA polymerase variant. J. Transl. Med. 18 (179) https://doi.org/ 10.1186/s12967-020-02344-6 (2020).

Qun, L., et al., 2020. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199–1207.

- Simmonds, P., 2020. Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-term Evolutionary Trajectories. https://doi.org/10.1128/mSphere.00408-20.
- Su, Y.C.F., et al., 2020. Discovery and Genomic Characterization of a 382-nucleotide Deletion on ORF7b and ORF8 During the Early Evolution of SARS-CoV-2. https:// doi.org/10.1128/mBio.01610-20.
- Subissi, L., et al., 2014. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc. Natl. Acad. Sci. U.S.A. 111 (37) https://doi.org/10.1073/pnas.1323705111.
- Wang, Q., et al., 2020. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell 182 (2), 417–428. https://doi.org/10.1016/j.cell.2020.05.034, 2020 e13.